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■ CASE REPORT ■
Introduction
Malignant mixed müllerian tumors (MMMTs) are un-
common neoplasms of the female genital tract that
are histologically defined by the presence of malignant
epithelial and stromal elements [1]. According to the
National Comprehensive Cancer Network clinical prac-
tice guidelines in oncology (2008), MMMT is classified
as a carcinosarcoma. This type of malignant tumor
can arise from any genital organ and occurs mainly in
the uterus; however, carcinosarcoma of the ovary is a
very rare tumor, which constitutes less than 1% of all
ovarian malignancies [2]. Ovarian carcinosarcoma is
characterized by aggressive behavior with rapid progres-
sion and poor prognosis, with few women with ovarian
carcinosarcoma surviving longer than a few years. Op-
timal debulking surgery followed by chemotherapy is
the treatment of choice for this type of malignancy [3].
We report a case of advanced primary ovarian car-
cinosarcoma, outlining the clinical features, pathologic
characteristics, and management.
Case Report
A 52-year-old woman, gravida 3, para 3, who went
through menopause at 50 years of age, with no history
of hormone therapy or major systemic disease except
for tubal ligation and appendectomy in 1979, began to
suffer from abdominal discomfort and gastrointestinal
upset for about 1 year. She had previously visited a gas-
troenterologist and taken medications for 3 months
without improvement of the symptoms. Shortly before-
hand, she had started to complain of abdominal disten-
tion and a firm palpable mass over her lower abdomen.
The patient was advised to visit a gynecologist for help,
but she hesitated and started taking Chinese herbal
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medicine for around 1 month. Unfortunately, enlarge-
ment of the mass was noted, and she finally decided to
visit our outpatient department.
Physical examination revealed a huge pelvic mass
and abdominal tenderness with mild rebounding pain.
Pelvic examination revealed a retracted cervix and bilat-
eral adnexal mass. Transvaginal ultrasound was per-
formed showing bilateral pelvic masses approximately
81 × 79 × 94 mm and 72 × 40 × 68 mm in size, with flow
and solid components. Malignancy was highly proba-
ble, and a computed tomography scan was arranged.
This scan revealed a multiloculated low-density lesion
with peripheral enhancement about 11.6 × 10 × 18 cm
from bilateral adnexa, with superior extension into the
abdomen, encasing the ileum and resulting in bilateral
hydronephrosis and hydroureter. Ovarian cancer with
intraperitoneal seeding was considered. There were no
specific findings on upper gastrointestinal endoscopy,
colonoscopy, and breast sonography.
Laboratory test results were generally within nor-
mal limits except for elevated lactate dehydrogenase
(662 U/L), high platelet count (492,000/mm3), and
low hemoglobin (11.1 g/dL). Tumor markers revealed
that serum α-fetoprotein was 1.46 ng/mL, carcinoem-
bryonic antigen was 1.44 ng/mL, cancer antigen (CA)
125 was 241 U/mL, CA 153 was 12.32 U/mL, and CA
199 was 17.34 U/mL.
The patient underwent exploratory laparotomy, and
huge bilateral ovarian tumors with abdominal carci-
nomatosis were noted. The tumors involved bilateral
ovaries and fallopian tubes, the uterine surface, cul-
de-sac, urinary bladder surface, pelvic wall, intestinal
wall, mesentery, and omentum. Frozen control tests
proved that the mass was malignant, and optimal de-
bulking surgery was performed. Grossly, the bilateral
ovarian tumors measured 12×8×7 cm and 8×6×4 cm
and were brown in color. Dissection of the tumors re-
vealed cystic and solid components with necrosis and
hemorrhaging.
Histologically, the ovarian tumors showed a pic-
ture consistent with the heterologous variety MMMT
composed of an epithelial element and a mesenchymal
element. The epithelial element was composed of endo-
metrioid glandular pattern. The mesenchymal element
was composed of spindle tumor cells (Figure 1) floating
in the cartilaginous matrix. Osteoid matrix formation
was also noted. The epithelial element was immunore-
active for cytokeratin (Figure 2), but the mesenchymal
element was not. Final diagnosis of primary heterolo-
gous ovarian MMMT stage IIIc was given.
Following the debulking surgery, adjuvant chemo-
therapy using ifosfamide and cisplatin every 3 weeks for
six cycles was initiated. Chemotherapy was administered
as follows: cisplatin 50 mg/m2 on day 1 and ifosfamide
1 g/m2 on day 1, day 2, and day 3 of each cycle. We
monitored the status of the disease using tumor marker
CA 125 and image studies. Levels of CA 125 decreased
to normal range after the first chemotherapy cycle.
Follow-up after completion of therapy showed no in-
crease in the tumor marker (Figure 3), and the com-
puted tomography scan did not disclose abdominal
recurrence.
Discussion
Carcinosarcoma is a biphasic tumor with malignant
epithelial and malignant mesenchymal elements. The
mesenchymal component usually contains heterolo-
gous elements such as cartilage, skeletal muscle, bone,
or fat [2,4]. This type of tumor is unusual and only a
few cases are reported each year, and these have a ten-
dency to be associated with less favorable outcomes.
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Figure 1. Mesenchymal element composed of spindle tumor
cells (hematoxylin and eosin, ×200).
Figure 2. Epithelial element immunoreactive for cytokeratin
(cytokeratin stain, ×200).
The majority of patients present with stage III–IV disease,
and approximately 75% of reported patients die of the
disease in an average of 12 months postoperatively.
The histogenesis of carcinosarcoma arising in the ovary
remains controversial. Theoretical origins include the
müllerian duct, mesoderm, and endometriosis [5].
The most common symptoms and signs of carci-
nosarcoma of the ovary are abdominal fullness and
abdominal mass [6,7]. CA 125 is a highly specific tumor
marker for ovarian tumors, especially for serous ade-
nocarcinoma, and it has also been shown to be a useful
tumor marker for ovarian carcinosarcoma. Histologi-
cally, the cytokeratin immunohistochemical staining is
positive in the epithelial element of carcinosarcoma.
Optimal debulking surgery represents the most real-
istic chance for long-term survival. In a series of studies,
the ability to achieve optimal cytoreduction was asso-
ciated with a statistically significant improvement in
survival [8,9]. However, radiotherapy may be appropri-
ate for patients with chemotherapy-refractory recurrent
or persistent disease that is restricted to the pelvis [10].
We report this case of primary heterologous carci-
nosarcoma of the ovary with advanced disease. After
optimal debulking surgery, six courses of combination
chemotherapy with ifosfamide and cisplatin were initi-
ated and finalized. At the time of writing, the patient
had been disease-free for 18 months with regular follow-
up examinations at our outpatient department. Ovarian
carcinosarcoma is definitely sensitive to platinum com-
pounds [4,11]. In a small non-randomized trial [12],
the rate of response to the combination of ifosfamide
and cisplatin was 33%. Subsequently, a large phase III
trial conducted by the Gynecology Oncology Group
compared single-agent ifosfamide [13] with the com-
bination of cisplatin and ifosfamide. Results showed
superior activity and only slightly improved progression-
free survival with this combination, with no difference in
terms of survival and at the cost of increased toxicity.
In another study [14], a total of 31 patients under-
went initial surgical treatment. Postoperative, neoad-
juvant chemotherapy consisted of 16 patients with
carboplatin/paclitaxel, 11 patients with ifosfamide/
cisplatin, one with cyclophosphamide/doxorubicin/
cisplatin, one with carboplatin alone, and two receiving
no further treatment. The progression-free survival inter-
val was improved with the use of ifosfamide/cisplatin
versus carboplatin/paclitaxel. The overall survival was
also significantly improved with the use of ifosfamide/
cisplatin (p = 0.03). Crotzer et al [15] reported the effi-
cacy and toxicity of cisplatin and ifosfamide in the
treatment of patients with MMMT of the ovary, with 
a response rate of 78% accompanied with a high inci-
dence of adverse effects. In conclusion, the doublet
cisplatin/ifosfamide should be the initial treatment for
ovarian carcinosarcoma, but higher toxicity should be
considered. Novel agents with activity against MMMT of
the ovary and acceptable toxicity are, therefore, needed.
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